Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
Open accessThe DOI matches its Crossref record; 111 of the 113 references it cites were found in a registry or an index.
Abstract
Drug discovery is an expensive, long, and complex process, usually with a high degree of uncertainty. In order to improve the efficiency of drug development, effective methods are demanded to screen lead molecules and eliminate toxic compounds in the preclinical pipeline. Drug metabolism is crucial in determining the efficacy and potential side effects, mainly in the liver. Recently, the liver-on-a-chip (LoC) platform based on microfluidic technology has attracted widespread attention. LoC systems can be applied to predict drug metabolism and hepatotoxicity or to investigate PK/PD (pharmacokinetics/pharmacodynamics) performance when combined with other artificial organ-on-chips. This review discusses the liver physiological microenvironment simulated by LoC, especially the cell compositions and roles. We summarize the current methods of constructing LoC and the pharmacological and toxicological application of LoC in preclinical research. In conclusion, we also discussed the limitations of LoC in drug discovery and proposed a direction for improvement, which may provide an agenda for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 (A) Cell distribution structure in a liver lobule. Double blood supply of hepatic arteriole and portal vein enters the liver’s portal triad region and the central vein. (B) Three-dimensional liver tissue diagram in LoC. The fluid flows through the pores on the scaffold, providing the biochemical environment and mechanical stimulation. (C) Microstructure of liver. The liver lobule is hexagonal, with a 1 mm diameter and a 2 mm thickness, functionally divided into three regions. (D) Example of zonal heterogeneity of hepatotoxicity. The yellow arrow shows the flow direction. (A,B) reproduced with permission of [34], Copyright © 2017. Published by Elsevier. (C,D) reproduced with permission of [29], Copyright © 2019. Published by MDPI.](https://figures.cochat.ai/paper-figures/8eeeeaa0612e4f01b3c2ef7d6ea2cc89/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-1.jpg)
![Figure 2 Different microfluidic models are used to construct liver-on-a-chip. (A) A 24-well PDMS mold with through holes at the bottom. Hepatocytes (labeled green) selectively adhered to the collagen structure, clustered together, and then surrounded by mouse 3T3-J2 fibroblasts (labeled orange). (B) Microfluidic endothelial-like barrier. The barrier consists of parallel channels connecting the cell culture zone with the external flow channel. (C) Simulation of liver lobules in Christmas tree structure, with gradient generator. (D) Spheroid culture. Cultured spheroids in an ultra-low-attachment plate, transferred them to a 96-well plate or liver chip and compared their performance. (A) reproduced with permission of [11], Copyright © 2008. Published by Nature Publishing Group. (B) reproduced with permission of [78], Copyright © 2007. Published by Wiley Periodicals, Inc. (C) reproduced with permission of [79], Copyright © 2018. Published by Nature Publishing Group. (D) reproduced with permission of [80], Copyright © 2022 Published by Elsevier.](https://figures.cochat.ai/paper-figures/1de44d36495d453cb996e1c2989e0ebf/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-2.jpg)
![Figure 3 Example of 3D perfusion platforms. (A) Twelve fluid-isolated bioreactors with connected cell culture plate (yellow) and pneumatic plate (gray). (B) Cross section diagram of the bioreactor, the membrane separates the upper cell culture plate from the lower pneumatic plate, and the micropump provides power for medium circulation in the channel. (C) OrganoPlate LiverTox model. The iHeps differentiated in 2D culture are harvested and seeded in OrganoPlate 2-lane through a liquid processor. Perfusion and organ channels were separated by phase guidance (PhG). (A,B) reproduced with permission of [16], Copyright © 2016. Published by The American Society for Pharmacology and Experimental Therapeutics. (C) reproduced with permission of [20], Copyright © 2021. Published by Elsevier.](https://figures.cochat.ai/paper-figures/f107793bd46a470f93f5a9f2f9afd983/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-3.jpg)
![Figure 4 Example of multi-organ chips platforms. (A) Multi-organ chips based on liver, intestinal, vascular, and kidney chips. Caco-2, HUVEC, HepG2, and HK-2 occupy one floor from top to bottom (B) Taking a two-layer chip assembly as an example, the system was built in the order of inoculating cells to a porous membrane, providing a cell culture medium and assembling chips. The peristaltic pump provides power for fluid. (C) The liver and lung cancer parts on chips are connected through a microchannel. Channel is also equipped with a stirrer-based micropump to provide power. The value in the arrow is the flow ratio. (D) Concept diagram of PK model based on the multi-organ chip. (A,B), reproduced with permission of [23], Copyright © 2020. Published by Elsevier. (C,D) reproduced with permission of [91], Copyright © 2020. Published by AIP Publishing.](https://figures.cochat.ai/paper-figures/52e904e88dce4befabedea31a2ed646a/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Real-time monitoring of metabolic processes; transparent and flexible adjustment of physiological conditions.”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [138]
In the citing paper
“Difficult manufacturing; challenging cell implantation; high costs; requires precise equipment; limited testing and analysis.”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 1×
“They are the most primitive cells in the cell line, which can differentiate into cells of a particular tissue type in vivo [65].”
BackgroundBhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305 · cited 1×
“Researchers used microfluidic devices to provide oxygen, shear stress, and other conditions for cell culture in vitro, pursuing better simulation of the physiological functions of tissue and organs [73].”
MethodConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
From 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763 · cited 1×
“Statistics show that the average development cost of a new drug is around two billion dollars [4].”
BackgroundHuman primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 2×
“Typical odels include 2D planar pri ary hepatocytes [36,37], 3 ri ted liver tissue [38–41], hepatocyte organoids [42], and liver-on-ac i [43–46].”
BackgroundControlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line
Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I., & Knowles, B. B. (1979) · Nature · doi:10.1038/282615a0 · Cited by 1,317 · cited 1×
“Immortalized liver cell lines, which can be manipulated with unlimited proliferation by inhibiting cellular senescence [58,59], are widely used in drug toxicology research in vitro.”
MethodGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 1×
“Hepatocytes, known as parenchymal cells, account for about 60% of liver cells [31].”
BackgroundMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 2×
“(A) reproduced with permission of [11], Copyright © 2008.”
BackgroundMethodOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · cited 1×
“Most drug failures in clinical trials because the existing models in preclinical development are not appropriate for predicting new compound toxicity or metabolism [5].”
BackgroundA human liver cell atlas reveals heterogeneity and epithelial progenitors
Aizarani, N., Saviano, A., Sagar, Mailly, L., Durand, S., Herman, J. S., Pessaux, P., Baumert, T. F., & Grün, D. (2019) · Nature · doi:10.1038/s41586-019-1373-2 · Cited by 1,147 · cited 1×
“In addition, PHHs with population heterogeneity are essential to reflect in drug testing [51].”
BackgroundBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Gerets, H. H. J., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., & Atienzar, F. A. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9208-4 · Cited by 698 · cited 1×
“Standard liver cell lines are derived from hepatocellular carcinoma (HCC) [60,61], such as Huh7, HepG2, and HepaRG.”
BackgroundTrends in clinical success rates and therapeutic focus
Dowden, H., & Munro, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00074-z · Cited by 649
Reproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511 · cited 2×
“[7] performed their studies on the human relevance of animal (rats, dogs) hepatotoxicity with 3D microfluidic liver chips.”
BackgroundLee, P. J., Hung, P. J., & Lee, L. P. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21360 · Cited by 509 · cited 2×
“In the first LoC reported in 2007 [78], microfluidic technology was used to simulate the endothelial barrier in the hepatic sinuses to protect liver cells from damage due to high shear stress (Figure 2B).”
MethodPichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G., & Maurel, P. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08600-3 · Cited by 433
A microfluidic 3D hepatocyte chip for drug toxicity testing
Toh, Y.-C., Lim, T. C., Tai, D., Xiao, G., van Noort, D., & Yu, H. (2009) · Lab on a Chip · doi:10.1039/b900912d · Cited by 419 · cited 2×
“Drug toxicity 3D microfluidics hepatocytes (rats) acetaminophen, diclofenac, quinidine, rifampin and ketoconazole multiplexed testing [21]”
BackgroundRamaiahgari, S. C., den Braver, M. W., Herpers, B., Terpstra, V., Commandeur, J. N. M., van de Water, B., & Price, L. S. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1215-9 · Cited by 364 · cited 1×
“They have diverse differentiation functions and stable phenotypes, but the CYP450 expression level is not as high as that of HepaRG cells when HepaRG cells differentiate into hepatocytes [62,63].”
BackgroundGuo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348 · cited 1×
“Standard liver cell lines are derived from hepatocellular carcinoma (HCC) [60,61], such as Huh7, HepG2, and HepaRG.”
BackgroundHuman Hepatocytes with Drug Metabolic Function Induced from Fibroblasts by Lineage Reprogramming
Du, Y., Wang, J., Jia, J., Song, N., Xiang, C., Xu, J., Hou, Z., Su, X., Liu, B., Jiang, T., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.008 · Cited by 320
Cell Lines: A Tool for In Vitro Drug Metabolism Studies
Gomez-Lechon, M., Donato, M., Lahoz, A., & Castell, J. (2008) · Current Drug Metabolism · doi:10.2174/138920008783331086 · Cited by 300 · cited 1×
“Immortalized liver cell lines, which can be manipulated with unlimited proliferation by inhibiting cellular senescence [58,59], are widely used in drug toxicology research in vitro.”
MethodElaut, G., Henkens, T., Papeleu, P., Snykers, S., Vinken, M., Vanhaecke, T., & Rogiers, V. (2006) · Current Drug Metabolism · doi:10.2174/138920006778017759 · Cited by 292
Abdel-Misih, S. R. Z., & Bloomston, M. (2010) · Surgical Clinics of North America · doi:10.1016/j.suc.2010.04.017 · Cited by 286
Ataç, B., Wagner, I., Horland, R., Lauster, R., Marx, U., Tonevitsky, A. G., Azar, R. P., & Lindner, G. (2013) · Lab on a Chip · doi:10.1039/c3lc50227a · Cited by 272
Microfluidics—downsizing large-scale biology
Mitchell, P. (2001) · Nature Biotechnology · doi:10.1038/90754 · Cited by 264 · cited 1×
“Microfluidics is a downsizing of biological separation and analysis techniques with a high surface-to-volume ratio, automation, and integration [71,72].”
MethodHuang, R., Xia, M., Sakamuru, S., Zhao, J., Shahane, S. A., Attene-Ramos, M., Zhao, T., Austin, C. P., & Simeonov, A. (2016) · Nature Communications · doi:10.1038/ncomms10425 · Cited by 259
Treyer, A., & Müsch, A. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120009 · Cited by 252 · cited 2×
“For example, primary human hepatocytes (PHHs), the gold standard of toxicity testing, will rapidly depolarize in vitro, and the drug clearance rate will also be significantly reduced unless they are cultured in a particular environment, such as collagen sandwich culture [13].”
BackgroundTakebe, T., Imai, R., & Ono, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12577 · Cited by 238 · cited 1×
“After the preclinical trial, 90% of the approved drugs may still fail during human clinical trials or FDA approval [2,3].”
BackgroundNew Insights into Functional Aspects of Liver Morphology
Malarkey, D. E., Johnson, K., Ryan, L., Boorman, G., & Maronpot, R. R. (2005) · Toxicologic Pathology · doi:10.1080/01926230590881826 · Cited by 236 · cited 9×
“Among them, cytochrome P450 (CYP450) enzymes are terminal oxygenases involved in nearly all phase I drug metabolism steps in the liver.”
BackgroundInfluentialColl, M., Perea, L., Boon, R., Leite, S. B., Vallverdú, J., Mannaerts, I., Smout, A., El Taghdouini, A., Blaya, D., Rodrigo-Torres, D., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.027 · Cited by 233 · cited 1×
“Common stem cell lines include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which can differentiate into various liver cells [66,67] and hematopoietic stem cells [68,69] with stable metabolic function and specific gene expression ability.”
BackgroundDeng, J., Wei, W., Chen, Z., Lin, B., Zhao, W., Luo, Y., & Zhang, X. (2019) · Micromachines · doi:10.3390/mi10100676 · Cited by 229 · cited 2×
“Distinct types of cells form complicated transmission networks and metabolic environments through autocrine and paracrine signal transduction [29,30].”
BackgroundEsch, M. B., Ueno, H., Applegate, D. R., & Shuler, M. L. (2016) · Lab on a Chip · doi:10.1039/c6lc00461j · Cited by 222
Wang, Y., Wang, H., Deng, P., Chen, W., Guo, Y., Tao, T., & Qin, J. (2018) · Lab on a Chip · doi:10.1039/c8lc00869h · Cited by 222
Beckwitt, C. H., Clark, A. M., Wheeler, S., Taylor, D. L., Stolz, D. B., Griffith, L., & Wells, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.023 · Cited by 208
Competency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
Ware, B. R., Berger, D. R., & Khetani, S. R. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv048 · Cited by 195 · cited 1×
“The iPSCs have resembled sensitivity as PHHs in detecting the degree of drug-induced liver injury [70].”
BackgroundA 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®
Bircsak, K. M., DeBiasio, R., Miedel, M., Alsebahi, A., Reddinger, R., Saleh, A., Shun, T., Vernetti, L. A., & Gough, A. (2021) · Toxicology · doi:10.1016/j.tox.2020.152667 · Cited by 192 · cited 4×
“(C) reproduced with permission of [20], Copyright © 2021.”
BackgroundMethodInfluentialCell-printed 3D liver-on-a-chip possessing a liver microenvironment and biliary system
Lee, H., Chae, S., Kim, J. Y., Han, W., Kim, J., Choi, Y., & Cho, D.-W. (2019) · Biofabrication · doi:10.1088/1758-5090/aaf9fa · Cited by 188
Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery
Hinkson, I. V., Madej, B., & Stahlberg, E. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00770 · Cited by 169 · cited 1×
“Drug development is a long, costly, and highly uncertain process that usually takes 10–15 years [1].”
BackgroundHuman iPSC-Derived Endothelial Cells and Microengineered Organ-Chip Enhance Neuronal Development
Sances, S., Ho, R., Vatine, G., West, D., Laperle, A., Meyer, A., Godoy, M., Kay, P. S., Mandefro, B., Hatata, S., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.02.012 · Cited by 167
Ma, L.-D., Wang, Y.-T., Wang, J.-R., Wu, J.-L., Meng, X.-S., Hu, P., Mu, X., Liang, Q.-L., & Luo, G.-A. (2018) · Lab on a Chip · doi:10.1039/c8lc00333e · Cited by 166 · cited 1×
“The medication molecules in blood can rapidly diffuse with the aid of sinusoidal endothelial cells, completing the material exchange with hepatocytes [34,35].”
BackgroundMORAVCOVÁ, A., ČERVINKOVÁ, Z., KUČERA, O., MEZERA, V., RYCHTRMOC, D., & LOTKOVÁ, H. (2015) · Physiological Research · doi:10.33549/physiolres.933224 · Cited by 165 · cited 2×
“Typical odels include 2D planar pri ary hepatocytes [36,37], 3 ri ted liver tissue [38–41], hepatocyte organoids [42], and liver-on-ac i [43–46].”
BackgroundAn In Vitro Human Liver Model by iPSC-Derived Parenchymal and Non-parenchymal Cells
Koui, Y., Kido, T., Ito, T., Oyama, H., Chen, S.-W., Katou, Y., Shirahige, K., & Miyajima, A. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.06.010 · Cited by 163 · cited 1×
“Common stem cell lines include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which can differentiate into various liver cells [66,67] and hematopoietic stem cells [68,69] with stable metabolic function and specific gene expression ability.”
BackgroundA high-throughput microfluidic assay to study neurite response to growth factor gradients
Kothapalli, C. R., van Veen, E., de Valence, S., Chung, S., Zervantonakis, I. K., Gertler, F. B., & Kamm, R. D. (2011) · Lab Chip · doi:10.1039/c0lc00240b · Cited by 161
3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies
Mueller, D., Krämer, L., Hoffmann, E., Klein, S., & Noor, F. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.06.024 · Cited by 159 · cited 1×
“They have diverse differentiation functions and stable phenotypes, but the CYP450 expression level is not as high as that of HepaRG cells when HepaRG cells differentiate into hepatocytes [62,63].”
BackgroundIsolation and Culture of Primary Human Hepatocytes
LeCluyse, E. L., Alexandre, E., Hamilton, G. A., Viollon-Abadie, C., Coon, D. J., Jolley, S., & Richert, L. (2004) · Basic Cell Culture Protocols · doi:10.1385/1-59259-838-2:207 · Cited by 157
In vitro platforms for evaluating liver toxicity
Bale, S. S., Vernetti, L., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., McCarty, W. J., Bakan, A., Bhushan, A., Shun, T. Y., et al. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214531872 · Cited by 155 · cited 1×
“As the largest internal organ, the liver plays a crucial role in regulating the homeostasis of the internal environment, the anabolism of various substances, and the detoxification of endogenous and exogenous substances, especially in drug metabolism [27,28].”
BackgroundLin, J. H., Chiba, M., Balani, S. K., Chen, I. W., Kwei, G. Y., Vastag, K. J., & Nishime, J. A. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08414-4 · Cited by 153 · cited 1×
“Especially the distinct variations in CYP450 induction by medications between humans and animals (rats, dogs) have been well established, obstructing their wide application [57].”
BackgroundHuman Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071629 · Cited by 152 · cited 1×
“The microporous array processed by the low-adhesion layer was used to improve the pooling of multiple spheroids [82,83], and successfully generated up to 100 spheroids (Figure 2D).”
MethodBarrile, R., van der Meer, A. D., Park, H., Fraser, J. P., Simic, D., Teng, F., Conegliano, D., Nguyen, J., Jain, A., Zhou, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1054 · Cited by 138
iPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery
Corbett, J. L., & Duncan, S. A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00265 · Cited by 138
An On-Chip Small Intestine–Liver Model for Pharmacokinetic Studies
Kimura, H., Ikeda, T., Nakayama, H., Sakai, Y., & Fujii, T. (2015) · SLAS Technology · doi:10.1177/2211068214557812 · Cited by 136 · cited 2×
“Drug metabolism 3D perfusion, co-culture, liver–small intestine Caco-2, HepG2, A549 epirubicin (EPI), irinotecan (CPT-11), and cyclophosphamide (CPA) reproduce both blood circulation and organs volume relation in vitro [90]”
BackgroundMethodCytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen.
Lewis, D. F., Ioannides, C., & Parke, D. V. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106633 · Cited by 130 · cited 1×
“In addition, since research animals are easily accessible commercially, they can be employed as sources of fresh primary cells without the limitation of donor shortage [55,56].”
BackgroundLiver-on-a-Chip models of fatty liver disease
Hassan, S., Sebastian, S., Maharjan, S., Lesha, A., Carpenter, A., Liu, X., Xie, X., Livermore, C., Zhang, Y. S., & Zarrinpar, A. (2020) · Hepatology · doi:10.1002/hep.31106 · Cited by 127
Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., Garcia-Ruiz, C., Konu, O., Miranda, J., Lunov, O., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.021 · Cited by 126
Developmentally inspired human ‘organs on chips’
Ingber, D. E. (2018) · Development · doi:10.1242/dev.156125 · Cited by 124 · cited 1×
“In contrast to organoids, microfluidic systems will not change shape over time and have strong repeatability and controllability, making them ideal for large-scale preclinical drug screening and testing [96].”
BackgroundMetabolic Patterning on a Chip: Towards in vitro Liver Zonation of Primary Rat and Human Hepatocytes
Kang, Y. B., Eo, J., Mert, S., Yarmush, M. L., & Usta, O. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27179-6 · Cited by 122 · cited 2×
“(C) reproduced with permission of [79], Copyright © 2018.”
BackgroundMethodMicrofluidic Organ-on-a-Chip System for Disease Modeling and Drug Development
Li, Z., Hui, J., Yang, P., & Mao, H. (2022) · Biosensors · doi:10.3390/bios12060370 · Cited by 120
Tsamandouras, N., Kostrzewski, T., Stokes, C. L., Griffith, L. G., Hughes, D. J., & Cirit, M. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237495 · Cited by 119 · cited 2×
“[19] applied the LoC platform in quantitative pharmacological research and analyzed hepatocytes from different donors.”
BackgroundMethodFoster, A. J., Chouhan, B., Regan, S. L., Rollison, H., Amberntsson, S., Andersson, L. C., Srivastava, A., Darnell, M., Cairns, J., Lazic, S. E., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02427-4 · Cited by 117 · cited 1×
“Hepatocytes derived from stem cells have emerged as a new source of liver cells in recent years [64].”
BackgroundMicroengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116 · cited 1×
“Engineers are using engineering tools to control the cellular microenvironment, such as semiconductor industrial tools, miniaturization tools, and integration with organs on chips, to improve the stability of PHHs’ functions [14].”
BackgroundHuman and animal hepatocytes in vitro with extrapolation in vivo
O'Brien, P. J., Chan, K., & Silber, P. M. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.003 · Cited by 114
Witowski, J. S., Pędziwiatr, M., Major, P., & Budzynski, A. Z. (2017) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-017-1527-3 · Cited by 113
Strategies for Improving the Maturity of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Tu, C., Chao, B. S., & Wu, J. C. (2018) · Circulation Research · doi:10.1161/circresaha.118.313472 · Cited by 113 · cited 1×
“In addition, cells derived from iPSCs are not entirely consistent with native liver cells, and their structure and function are immature [102].”
BackgroundMaterne, E.-M., Tonevitsky, A. G., & Marx, U. (2013) · Lab on a Chip · doi:10.1039/c3lc50240f · Cited by 112
Three-dimensional cell culture technique and pathophysiology
Matsusaki, M., Case, C. P., & Akashi, M. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.003 · Cited by 111
Can animal data predict human outcome? Problems and pitfalls of translational animal research
Martić-Kehl, M. I., Schibli, R., & Schubiger, P. A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2175-z · Cited by 110
In Vitro Generation of Functional Liver Organoid-Like Structures Using Adult Human Cells
Ramachandran, S. D., Schirmer, K., Münst, B., Heinz, S., Ghafoory, S., Wölfl, S., Simon-Keller, K., Marx, A., Øie, C. I., Ebert, M. P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139345 · Cited by 109
Generation of mature kupffer cells from human induced pluripotent stem cells
Tasnim, F., Xing, J., Huang, X., Mo, S., Wei, X., Tan, M.-H., & Yu, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.016 · Cited by 107 · cited 1×
“Common stem cell lines include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which can differentiate into various liver cells [66,67] and hematopoietic stem cells [68,69] with stable metabolic function and specific gene expression ability.”
BackgroundAutomated microfluidic cell culture of stem cell derived dopaminergic neurons
Kane, K. I. W., Moreno, E. L., Hachi, S., Walter, M., Jarazo, J., Oliveira, M. A. P., Hankemeier, T., Vulto, P., Schwamborn, J. C., Thoma, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-34828-3 · Cited by 105 · cited 1×
“In 2019, a study described the automatic imaging program of the liver-on-a-chip [106], and some other scholars tried to use 3D printing technology to design and create a chip stent for this organ chip later [107].”
BackgroundSarkar, U., Rivera‐Burgos, D., Large, E. M., Hughes, D. J., Ravindra, K. C., Dyer, R. L., Ebrahimkhani, M. R., Wishnok, J. S., Griffith, L. G., & Tannenbaum, S. R. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063495 · Cited by 101
Long, T. J., Cosgrove, P. A., Dunn, R. T., Stolz, D. B., Hamadeh, H. K., Afshari, C. A., McBride, H. J., & Griffith, L. G. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071456 · Cited by 99 · cited 5×
“[16] carried out a similar study with the same 3D perfusable human liver co-culture platform (Figure 3A,B).”
BackgroundMethodInfluentialIntroducing an automated high content confocal imaging approach for Organs-on-Chips
Peel, S., Corrigan, A. M., Ehrhardt, B., Jang, K.-J., Caetano-Pinto, P., Boeckeler, M., Rubins, J. E., Kodella, K., Petropolis, D. B., Ronxhi, J., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00829a · Cited by 98 · cited 1×
“In 2019, a study described the automatic imaging program of the liver-on-a-chip [106], and some other scholars tried to use 3D printing technology to design and create a chip stent for this organ chip later [107].”
BackgroundFunctional properties of hepatocytes in vitro are correlated with cell polarity maintenance
Zeigerer, A., Wuttke, A., Marsico, G., Seifert, S., Kalaidzidis, Y., & Zerial, M. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.11.027 · Cited by 93
Modeling alcohol-associated liver disease in a human Liver-Chip
Nawroth, J. C., Petropolis, D. B., Manatakis, D. V., Maulana, T. I., Burchett, G., Schlünder, K., Witt, A., Shukla, A., Kodella, K., Ronxhi, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109393 · Cited by 88 · cited 1×
“These similar membrane-based 2D platforms are widely used in hepatotoxicity assessment [80] and disease modeling [81].”
BackgroundUsta, O. B., McCarty, W. J., Bale, S., Hegde, M., Jindal, R., Bhushan, A., Golberg, I., & Yarmush, M. L. (2015) · TECHNOLOGY · doi:10.1142/s2339547815300012 · Cited by 85
Baran, S. (2022) · ALTEX · doi:10.14573/altex.2112203 · Cited by 77 · cited 2×
“Prior to the invention of the LoC, primary isolated hepatocytes and immortalized cell lines were used in preclinical drug hepatotoxicity testing [84].”
BackgroundMethodYi, F., Liu, G.-H., & Belmonte, J. C. I. (2012) · Protein & Cell · doi:10.1007/s13238-012-2918-4 · Cited by 69
Three-dimensional (3D) printing of mouse primary hepatocytes to generate 3D hepatic structure
Kim, Y., Kang, K., Jeong, J., Paik, S. S., Kim, J. S., Park, S. A., Kim, W. D., Park, J., & Choi, D. (2017) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2017.92.2.67 · Cited by 69
Docci, L., Milani, N., Ramp, T., Romeo, A. A., Godoy, P., Franyuti, D. O., Krähenbühl, S., Gertz, M., Galetin, A., Parrott, N., et al. (2022) · Lab on a Chip · doi:10.1039/d1lc01161h · Cited by 66 · cited 1×
“[87] evaluated metabolic enzyme activity using 15 drugs on the LoC system.”
MethodDevelopment of a Patient-Specific 3D-Printed Liver Model for Preoperative Planning
Madurska, M. J., Poyade, M., Eason, D., Rea, P., & Watson, A. J. M. (2017) · Surgical Innovation · doi:10.1177/1553350616689414 · Cited by 58
Shinha, K., Nihei, W., Ono, T., Nakazato, R., & Kimura, H. (2020) · Biomicrofluidics · doi:10.1063/5.0011545 · Cited by 58
Selective and tunable gradient device for cell culture and chemotaxis study
Kim, D., Lokuta, M. A., Huttenlocher, A., & Beebe, D. J. (2009) · Lab on a Chip · doi:10.1039/b901613a · Cited by 56
Liver microphysiological platforms for drug metabolism applications
Kulsharova, G., & Kurmangaliyeva, A. (2021) · Cell Proliferation · doi:10.1111/cpr.13099 · Cited by 52 · cited 1×
“The LoC system can also be integrated into the laboratory as preclinical tests to predict in vitro human experiments [15].”
BackgroundDixit, V. S., Moore, A., Tsao, H., & Hariparsad, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067173 · Cited by 51 · cited 1×
“which is the expression induction ability of drug metabolism enzymes (such as CYP) [86].”
BackgroundA Microfluidic 3D Hepatocyte Chip for Hepatotoxicity Testing of Nanoparticles
Li, L., Gokduman, K., Gökaltun, A., Yarmush, M. L., & Usta, O. B. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0086 · Cited by 49
Liu, D., Jiao, S., Wei, J., Zhang, X., Pei, Y., Pei, Z., Li, J., & Du, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119669 · Cited by 48
Gurevich, I., Burton, S. A., Munn, C., Ohshima, M., Goedland, M. E., Czysz, K., & Rajesh, D. (2020) · Biology Open · doi:10.1242/bio.055087 · Cited by 46
State-of-the-art liver disease research using liver-on-a-chip
Deguchi, S., & Takayama, K. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00248-0 · Cited by 46 · cited 1×
“The LoC system can also explore how the internal structure of the liver, such as the hepatic vascular system, is affected by oxygen and nutrient gradients, thereby simulating chronic liver disease in vitro [25,26] and searching for candidate drugs for the disease.”
BackgroundMicroscopic Imaging Methods for Organ-on-a-Chip Platforms
Buchanan, B. C., & Yoon, J. (2022) · Micromachines · doi:10.3390/mi13020328 · Cited by 44
Rowe, C., Shaeri, M., Large, E. M., Cornforth, T. V., Robinson, A., Kostrzewski, T. M., Sison-Young, R. L. C., Goldring, C. E., Park, K., & Hughes, D. J. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.09.012 · Cited by 41
Microphysiological systems in absorption, distribution, metabolism, and elimination sciences
Ness, K. P. V., Cesar, F., Yeung, C. K., Himmelfarb, J., & Kelly, E. J. (2021) · Clinical and Translational Science · doi:10.1111/cts.13132 · Cited by 40
Deguchi, S., Tsuda, M., Kosugi, K., Sakamoto, A., Mimura, N., Negoro, R., Sano, E., Nobe, T., Maeda, K., Kusuhara, H., et al. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00642 · Cited by 39
In vitro Liver Zonation of Primary Rat Hepatocytes
Tomlinson, L., Hyndman, L., Firman, J. W., Bentley, R., Kyffin, J. A., Webb, S. D., McGinty, S., & Sharma, P. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00017 · Cited by 38
Xiao, R., Lv, T., Tu, X., Li, P., Wang, T., Dong, H., Tu, P., & Ai, X. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27931 · Cited by 38 · cited 2×
“[22] chose to focus on PHHs, the gold standard of drug testing, to improve and stabilize cell functions and metabolic enzyme activity by using cell-extracellular matrix (ECM) interaction.”
BackgroundLiver-on-a-chip: Considerations, advances, and beyond
Yang, Z., Liu, X., Cribbin, E. M., Kim, A. M., Li, J. J., & Yong, K. (2022) · Biomicrofluidics · doi:10.1063/5.0106855 · Cited by 36 · cited 2×
“Moreover, with the recent rise of nanomedicine in the application of vaccines, the LoC system an co uct abundant and accurate research on the toxicity of na omedicines [47], making up for the lack of nanotoxicity assessment.”
BackgroundLiver-on-a-chip platform to study anticancer effect of statin and its metabolites
Chen, P.-Y., Hsieh, M.-J., Liao, Y.-H., Lin, Y.-C., & Hou, Y. (2020) · Biochemical Engineering Journal · doi:10.1016/j.bej.2020.107831 · Cited by 34 · cited 1×
“Multiple liver chip platforms have been designed to model drug metabolism [16–19], hepatotoxicity [7,20–22], drug–drug interactions [16,23], cancer [24], and inflammation [18].”
BackgroundCox, B., Barton, P., Class, R., Coxhead, H., Delatour, C., Gillent, E., Henshall, J., Isin, E. M., King, L. M., & Valentin, J. (2022) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2022.100054 · Cited by 34 · cited 1×
“The microporous array processed by the low-adhesion layer was used to improve the pooling of multiple spheroids [82,83], and successfully generated up to 100 spheroids (Figure 2D).”
MethodOn chip two-photon metabolic imaging for drug toxicity testing
Yu, F., Zhuo, S., Qu, Y., Choudhury, D., Wang, Z., Iliescu, C., & Yu, H. (2017) · Biomicrofluidics · doi:10.1063/1.4983615 · Cited by 32 · cited 1×
“Nevertheless, this method is often used for expensive and professional equipment, such as two-photon microscopy [105].”
MethodDocci, L., Klammers, F., Ekiciler, A., Molitor, B., Umehara, K., Walter, I., Krähenbühl, S., Parrott, N. J., & Fowler, S. M. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00482-9 · Cited by 31
Predicting Metabolism‐Related Drug–Drug Interactions Using a Microphysiological Multitissue System
Lohasz, C., Bonanini, F., Hoelting, L., Renggli, K., Frey, O., & Hierlemann, A. R. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000079 · Cited by 31 · cited 2×
“Drug-drug interactions gravity-driven microfluidic, liver–intestines PHHs, HCT116 cyclophosphamide, ifosfamide, ritonavir quantization of the impact of other drugs on the efficacy of anticancer drugs [92]”
BackgroundThe Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review
Özkan, A., Stolley, D. L., Cressman, E. N. K., McMillin, M., DeMorrow, S., Yankeelov, T. E., & Rylander, M. N. (2020) · Micromachines · doi:10.3390/mi11050487 · Cited by 30 · cited 1×
“The LoC system can also explore how the internal structure of the liver, such as the hepatic vascular system, is affected by oxygen and nutrient gradients, thereby simulating chronic liver disease in vitro [25,26] and searching for candidate drugs for the disease.”
BackgroundEckstrum, K., Striz, A., Ferguson, M. S., Zhao, Y., & Sprando, R. L. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.112828 · Cited by 27 · cited 2×
“These similar membrane-based 2D platforms are widely used in hepatotoxicity assessment [80] and disease modeling [81].”
BackgroundMethodInnovation for hepatotoxicity in vitro research models: A review
Han, W., Wu, Q., Zhang, X., & Duan, Z. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3711 · Cited by 23 · cited 1×
“Common flaws in these models include rapid activity decline and decreased expression of genes and function specific to the liver [88].”
BackgroundLohasz, C., Loretan, J., Sterker, D., Görlach, E., Renggli, K., Argast, P., Frey, O., Wiesmann, M., Wartmann, M., Rausch, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785851 · Cited by 17 · cited 1×
“Manual positioning and manipulation of organ chips for image acquisition are variable and time-consuming, and the amount of data is limited [104].”
BackgroundKorelova, K., Jiroušková, M., Sarnová, L., & Gregor, M. (2019) · Journal of Visualized Experiments · doi:10.3791/60507 · Cited by 15
Tetsuka, K., Ohbuchi, M., Kawabe, T., Goto, T., Kiyonaga, F., Takama, K., Yamazaki, S., & Fujimori, A. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01070 · Cited by 15 · cited 1×
“The throughput of this scale will inevitably pose obstacles to high-throughput screening when subsequent research is accelerated [109].”
BackgroundKorelova, K., Jiroušková, M., Sarnová, L., et al. (2019) · Journal of Visualized Experiments · doi:10.3791/60507-v · Cited by 3
The emergence of the circadian clock network in hiPSC-derived hepatocytes on chip
Gagliano, O., Cascione, S., Michielin, F., & Elvassore, N. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.02.046 · Cited by 2
Cited by
Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation
Gimondi, S., Ferreira, H., Reis, R. L., & Neves, N. M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01117 · Cited by 376
Application of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Alexandre-Franco, M. F., Kouider, R., Alkarany, R. A.-K., Correa, E. M. C., & Abdulla, A. A.-K. (2024) · Micromachines · doi:10.3390/mi15091137 · Cited by 55
Brain organoids-on-chip for neural diseases modeling: History, challenges and trends
Zhang, H., Huang, N., Bian, S., & Sawan, M. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101323 · Cited by 37
“This enables deeper insights into human responses to drugs and external stimuli, thereby pushing the boundaries of biomimicry in biological systems [26].”
Fayazbakhsh, F., Hataminia, F., Eslam, H. M., Ajoudanian, M., Kharrazi, S., Sharifi, K., & Ghanbari, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-47291-6 · Cited by 27
Metadata
- Authors
- Fu, J., Qiu, H., & Tan, C. S.
- Affiliations
- Tianjin University (CN)
- Tianjin University of Technology (CN)
- Corresponding author
- Qiu, Hailong
- Tan, Cherie S.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-04-21
- Volume
- 15
- Issue
- 4
- Pages
- 1300
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC10141038
- OpenAlex
- W4366773405
- Cited by
- 42
- References
- 113
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 2 · 2023: 2
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (22274110, 22250610197, 51872198, 21904094, 2021-JCJQ-JJ-0639, GG20210301)
- National Defense Science and Technology 173 Program (22274110, 22250610197, 51872198, 21904094, 2021-JCJQ-JJ-0639, GG20210301)
- National Key Research and Development Program of China (22274110, 22250610197, 51872198, 21904094, 2021-JCJQ-JJ-0639, GG20210301)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- liver-on-a-chip, organ-on-a-chip, preclinical drug discovery, drug metabolism, hepatotoxicity prediction, pharmacokinetics/pharmacodynamics, liver microenvironment, drug screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.